Cardiology Research Institute, Tomsk National Research Medical Center
https://doi.org/10.15829/1560-4071-2020-3388
Abstract
Aim. To test the hypothesis that the combined use of ivabradine (If inhibitor) and ranolazine (late sodium channel blocker) can reduce the ventricular rate in patients with permanent atrial fibrillation (AF) resistant to standard heart rate-lowering therapy.
Material and methods. The study included 25 patients with a permanent AF and an uncontrolled ventricular rate. All patients had NYHA class I-III heart failure with preserved ejection fraction. Patients took ivabradine 2,5 mg twice daily and ranolazine 250 mg twice daily. Twenty-four Holter monitoring was performed after 1, 2, 4 weeks and at the end of the study. The follow-up lasted 8 weeks.
Results. In 68% and 16% of patients, strict and lenient rate control was achieved, respectively. There was no ventricular rate decrease in 12% of patients. Adverse effects developed in 4% of subjects.
Conclusion. The combined use of ivabradine and ranolazine in patients with a permanent AF and uncontrolled ventricular rate reduces the rate without QT prolongation or reducing left ventricular contractile function. The findings support the hypothesis that the suppression of If current and dominant fibrillation frequency may be a new goal of permanent AF therapy. Prospective, randomized studies are needed to determine the role of drugs for ventricular rate control in patients with permanent AF and to study the effects on efficacy, safety, hospitalization frequency, and other clinical outcomes.
About the Authors
B. A. Tatarsky
Almazov National Medical Research Center
Russian Federation
Competing Interests: not
Russian Federation
St. Petersburg
Competing Interests: not
N. V. Kazennova
Almazov National Medical Research Center
Russian Federation
Competing Interests: not
Russian Federation
St. Petersburg
Competing Interests: not
R. E. Batalov
Cardiology Research Institute, Tomsk National Research Medical Center
Russian Federation
Competing Interests: not
Russian Federation
Competing Interests: not
S. V. Popov
Cardiology Research Institute, Tomsk National Research Medical Center
Russian Federation
Competing Interests: not
Russian Federation
Competing Interests: not
References
1. Kirchhof P, Bax J, Blomstrom-Lundquist C. et al. Early and comprehensive managemen to atrial fibrillation: executive summary of the proceedings from the 3nd AFNET-EHRA consensus conference “Research perspectives in AF”. Europace. 2012; 14,8-27 doi:10.1093/europace/eur 241
2. Aliot E, Botto GL, Crijns HJ. et al. Quality of life in patients with atrial fibrillation: how to assess it and how to improve it. Europace. 2014; 16(6):787-96. doi: 10.1093/europace/eut369
3. Wyse D, Waldo A, DiMarco, J. et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825-1833. doi:10.1056/NEJMoa021328
4. January CT, Wann LS, Calkins H, et al. AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation, Journal of the American College of Cardiology. 2019. pii: S1547-5271(19)30037-2. doi: 10.1016/j.hrthm.2019.01.024.
5. Fauchier L, Grimard C, Pierre B. et al. Comparison of beta blocker and digoxin alone and in combination for management of patients with atrial fibrillation and heart failure. Am J Cardiol.2009;103:248-54. doi:10.1016/j.amjcard.2008.09.064
6. Olshansky B, Rosenfeld LE, Warner AL. et al. AFFIRM Investigators, The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol. 2004; 43(7):1201-8 doi:10.1016/j.jacc.2003.11.032
7. Kirchhof P, Benussi S, Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J.2016;37(38):2893-2962doi: 10.1093/eurheartj/ehw210
8. Herrmann S, Layh B, Ludwig A. Novel insights into the distribution of cardiac HCN channels: an expression study in the mouse heart. J Mol Cell Cardiol 2011;51:997-1006. doi: 10.1016/j.yjmcc.2011.09.005
9. Verrier R., Bonatti R, Silva A.et al. If inhibition in the atrioventricular node by ivabradine causes rate-dependent slowing of conduction and reduces ventricular rate during atrial fibrillation. Heart Rhythm 2014;11:2288–2296. doi: 10.1016/ j.hrthm.2014.08.007
10. Moubarak G., Logeart D., Cazeau, S. et al. Might ivabradine be useful in permanent atrial fibrillation? Int J Cardiol 2014;175:187–188. doi:10.1016/ j.ijcard.2014.04.183.
11. Kosiuk J, Oebel S, John S. et al. Ivabradine for rate control in atrial fibrillation. Int J Cardiol179:27-28doi: 10.1016/ j.ijcard.2014.10.062
12. Wongcharoen W, Ruttanaphol A, Gunaparn S. et al. .Ivabradine reduced ventricular rate in patients with non-paroxysmal atrial fibrillation. Int J Cardiol. 2016. 1;224:252-255. doi: 10.1016/j.ijcard.2016.09.044
13. Daniels JD, Hill JA. Funny and late: targeting currents governing heart rate in atrial fibrillation. J Cardiovasc Electrophysiol. 2015. 26; 3:336-8. doi: 10.1111 /jce.12597
14. Black-Maier E., Pokorney S. D., Barnett A. S. Ranolazine reduces atrial fibrillatory wave frequency. Europace 2017, 19;7:1096-1100 doi: 10.1093/ europace/euw200
15. Verrier RL., Silva AF., Bonatti R. Combined Actions of Ivabradine and Ranolazine Reduce Ventricular Rate During Atrial Fibrillation. J Cardiovasc Electrophysiol 2014; 26:329-335.doi: 10.1111/jce.12569
Review
For citations:
Tatarsky B.A., Kazennova N.V., Batalov R.E., Popov S.V. Cardiology Research Institute, Tomsk National Research Medical Center. Russian Journal of Cardiology. 2020;25(7):3388. (In Russ.) https://doi.org/10.15829/1560-4071-2020-3388
Views:
1376
Email this article 